OmniaSecure

Written By Randy Wu

What is OmniaSecure?

OmniaSecure is a small-diameter defibrillation lead developed by Medtronic for implantable cardioverter defibrillators (ICDS). A defibrillation lead is a wire that connects the ICD to the heart, allowing the device to monitor heart rhythms and send electrical shocks to control dangerous arrhythmias. OmniaSecure was recently FDA approved in 2025 and is the world’s smallest defibrillation lead at 4.7 French (1.6 mm) in diameter.

Why is OmniaSecure Important?

Traditional ICD leads tend to be larger, increasing the risk of complications such as lead fractures, blood vessel blockage, or tricuspid valve damage. OmniaSecure addresses these risks, as a smaller catheter allows more precise placement inside the heart while providing defibrillation therapy to patients with life-threatening arrhythmias. 

Clinical Trial Results:

From the LEADR Global Pivotal Trial in 2024, researchers found that OmniaSecure was extremely successful:

  • 97.9% implant success rate

  • 97.5% defibrillation success at implant

  • 96.5% free from major lead-related complications after 3 years

  • 99.8% fracture-free survival during follow-ups

  • 98.2% fracture-free rate over 10 years

Risks and Complications:

Although OmniaSecure is extremely safe according the trials, complications can still arise:

  • Lead dislodgement

  • Heart perforation

  • Inappropriate shocks

  • Blood vessel injury

  • Arrhythmias

OmniaSecure is a major advancement in the implant of defibrillators because it is the world’s smallest defibrillation lead and shows extremely successful results. Researchers are continuing to study OmniaSecure in newer techniques and broader patient populations.

Randy Wu
Next

MYQORZO